XML 68 R55.htm IDEA: XBRL DOCUMENT v3.20.2
Collaborative Agreements (Details)
 1 Months Ended 3 Months Ended 6 Months Ended
Apr. 11, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 29, 2017
Aug. 07, 2015
product
Jun. 30, 2020
USD ($)
Apr. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Jan. 31, 2020
USD ($)
Aug. 30, 2019
USD ($)
Oct. 31, 2018
USD ($)
Mar. 31, 2018
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Revenues                         $ 267,187 $ 135,673   $ 1,594,461 $ 2,965,579  
Grant funding liability         $ 10,330,235               10,330,235     10,330,235   $ 6,065,212
Collaborative Arrangement, Product                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Accounts receivable         2,900,000               2,900,000     2,900,000    
ApolloBio | Collaborative Arrangement, Product                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Territory expansion option period     3 years                              
Proceeds received in upfront payment                     $ 19,400,000              
Upfront payment received                     23,000,000.0       $ 23,000,000.0 23,000,000.0    
Advisory fees                     960,000              
Additional revenue to be achieved                               $ 20,000,000.0    
Royalty period                               10 years    
Period from effective date for termination                               1 year    
Number of days written notice before termination                               90 days    
ApolloBio | Collaborative Arrangement, Product | Foreign Tax Authority                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Foreign corporate income taxes reducing upfront payment                     2,200,000              
Foreign non-corporate income taxes reducing upfront payment                     $ 1,400,000              
AstraZeneca                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Revenues                         74,000 62,000   $ 146,000 2,800,000  
AstraZeneca | Collaborative Arrangement, Product                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Upfront payment received   $ 27,500,000                   $ 27,500,000            
Anticipated development and regulatory event based payment receivable milestones                               125,000,000    
Anticipated commercial event based payment receivable milestones                               115,000,000    
Number of additional products to be developed | product       2                            
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Collaborative agreement, funding to be received           $ 6,900,000                        
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | Lassa Fever And MERS Vaccine                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Collaborative agreement, funding to be received $ 56,000,000                                  
Collaborative agreement, period to receive funding for research and development 5 years                                  
Funding received for research and development                         1,800,000 1,500,000   2,900,000 3,200,000  
Grant funding liability         5,300,000               5,300,000     5,300,000    
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | SARS-CoV-2/COVID-19 Vaccine                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Collaborative agreement, funding to be received               $ 9,000,000.0                    
Funding received for research and development                         5,800,000     8,100,000    
Grant funding liability         101,000               101,000     101,000    
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Collaborative agreement, funding to be received           5,000,000.0                        
Funding received for research and development                               0    
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | INO-4800                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Collaborative agreement, funding to be received           $ 1,300,000                        
Bill And Melinda Gates Foundation | Collaborative Arrangement, Product | DNA-Encoded Monoclonal Antibody Technology                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Funding received for research and development                 $ 1,100,000 $ 2,200,000     36,000 $ 698,000   170,000 $ 1,800,000  
Grant funding liability         858,000               858,000     858,000    
Bill And Melinda Gates Foundation | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Funding received for research and development             $ 5,000,000.0           850,000     913,000    
Grant funding liability         4,100,000               4,100,000     4,100,000    
Department Of Defence [Member] | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Funding received for research and development         54,500,000               0          
Grant funding liability         0               $ 0     $ 0    
Department Of Defence [Member] | Collaborative Arrangement, Product | CELLECTRA 2000 Device                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Purchase price, procurement contract         $ 16,600,000